Neoadjuvant PD-1 Blockade with Sintilimab in Mismatch-Repair Deficient Rectal Cancer: An Open-Label Clinical Trial



Neoadjuvant PD-1 Blockade with Sintilimab in Mismatch-Repair Deficient Rectal Cancer: An Open-Label Clinical Trial



Neoadjuvant PD-1 Blockade with Sintilimab in Mismatch-Repair Deficient Rectal Cancer: An Open-Label Clinical Trial



Neoadjuvant PD-1 Blockade with Sintilimab in Mismatch-Repair Deficient Rectal Cancer: An Open-Label Clinical Trial

Cancer is a leading cause of death worldwide and rectal cancer is one of the most common types of cancer. A new clinical trial has been conducted to evaluate the efficacy of neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient rectal cancer.

Background

The prognosis of mismatch-repair deficient (MMR-D) rectal cancer is poor due to the lack of effective therapies. Neoadjuvant PD-1 blockade with sintilimab has been shown to be effective in other cancer types, but its efficacy in MMR-D rectal cancer is unknown.

Methods

This was an open-label, single-arm clinical trial conducted at the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, China. Eligible patients had histologically confirmed MMR-D rectal cancer and were treated with neoadjuvant PD-1 blockade with sintilimab. The primary endpoint was the objective response rate (ORR).

Results

A total of 28 patients were enrolled in the trial. The median age was 55 years (range: 33-73 years). The ORR was 71.4% (95% CI: 54.1-88.7%). The median progression-free survival (PFS) was 8.3 months (95% CI: 4.2-12.4 months).

Conclusion

This study demonstrated that neoadjuvant PD-1 blockade with sintilimab is an effective treatment for MMR-D rectal cancer. Further studies are needed to confirm these findings and to determine the optimal dose and schedule for sintilimab in this setting.

Summary: This open-label clinical trial evaluated the efficacy of neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient rectal cancer. The results showed that the objective response rate was 71.4% and the median progression-free survival was 8.3 months. These findings suggest that sintilimab may be an effective treatment for MMR-D rectal cancer, however, further studies are needed to confirm these results.

#Neoadjuvant #PD1Blockade #Sintilimab #MismatchRepair #RectalCancer #ClinicalTrial #HEALTH

Related Posts